Comparing the rectal Indomethacin plus Mesna versus rectal indomethacin on prevention of post Endoscopic Retrograde Cholangio-pnacreatography pancreatitis

Effect of indomethacin suppository plus mesna injection verusus indomethacin suppository in prevention of post Endoscopic Retrograde Cholangio-pnacreatography pancreatitis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20121021011192N16

Enrollment

698

Registered

2023-10-13

Start date

2023-09-23

Completion date

Unknown

Last updated

2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatitis. Other acute pancreatitis

Interventions

Intervention 1: Intervention group: Administration of single dose of 100 mg rectal Indomethacine plus 400 mg infusion of mesna 1 hours before doing Endoscopic cholangiopancreatograph. Intervention 2:

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients undergoing ERCP in Taleghani hospital by taking written consent

Exclusion criteria

Exclusion criteria: Patients history of hypersensitivity against each of indomethacin or mesna Patients history of sphinctrotomy

Design outcomes

Primary

Measure	Time frame
Pancreatitis. Timepoint: 10 days after doing Endoscopic Retrograde Cholangio-pancreatography. Method of measurement: Clinical evaluation.	—

Secondary

Measure	Time frame
Gastrointestinal bleeding. Timepoint: 10 days after doing Endoscopic Retrograde Cholangio-pancreatography. Method of measurement: Clinical evaluation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Abbasinazari

Shahid Beheshti University of Medical Sciences

m_abbasi@sbmu.ac.ir+98 21 8887 3704

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026